Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced that the US Food and Drug Administration (FDA) has approved Tradjenta (linagliptin), a dipeptidyl peptidase-4 inhibitor used to lower blood sugar in adults with type 2 diabetes.
Tradjenta can be used as monotherapy or in combination with metformin, sulfonylurea or pioglitazone.
When used as monotherapy, Tradjenta showed significant A1C reductions of up to 0.7%, and reductions of 0.5% when used in combination with pioglitazone.
Adverse affects observed with the use of the drug include nasopharyngitis, hypoglycaemia, and pancreatitis.
Tradjenta is under regulatory review in the EU and Japan.